Atlas Trials

Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma

Clinical trial NCT00509379 · COMPLETED

Trial details

NCT number
NCT00509379
Sponsor
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
LymphomaNon-Hodgkin Lymphoma
Start date
2006-09-01
Primary completion
2007-11-01
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.